Literature DB >> 40644

The effects of neuroleptics with central dopamine and noradrenaline receptor blocking properties in the L-DOPA and (+)-amphetamine-induced waking EEG in the rat.

J M Monti.   

Abstract

1 A study was carried out in rats (prepared for chronic sleep recording) of the effects of pretreatment with neuroleptics differing in their relative antinoradrenaline and antidopamine receptor potencies, on the L-DOPA and (+)-amphetamine-induced increase in waking EEG. 2 Haloperidol (0.6 mg/kg), which blocks central dopamine and noradrenaline (NA) receptors, reversed the EEG desynchronizing actions of L-DOPA and (+)-amphetamine. 3 Low doses of pimozide (0.4 to 0.8 mg/kg) which block dopamine receptors exclusively, were not able to modify the pharmacologically induced disruption of the sleep-awake cycle. However, at 1 mg/kg, a dose which also produces blockade of NA receptors, pimozide counteracted the increase in waking elicited by (+)-amphetamine. 4 Spiroperidol (1 to 4 mg/kg) which is devoided of NA receptor blocking properties, failed to reverse the L-DOPA or (+)-amphetamine-induced arousal. 5 Our results suggest that the increased waking time observed after the catecholamine agonists is related to an increased availability of NA rather than dopamine.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 40644      PMCID: PMC2043609     

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  10 in total

1.  Electrocortical changes induced by perfusion of catecholamines into the brainstem reticular formation.

Authors:  B J Key
Journal:  Neuropharmacology       Date:  1975-01       Impact factor: 5.250

2.  The actions of dihydroxyphenylalanine and dihydroxyphenylserine on the sleep-wakefulness cycle of the rat after peripheral decarboxylase inhibition.

Authors:  H Altier; M Moldes; J M Monti
Journal:  Br J Pharmacol       Date:  1975-05       Impact factor: 8.739

3.  Does dopamine have a role in schizophrenia?

Authors:  A Carlsson
Journal:  Biol Psychiatry       Date:  1978-02       Impact factor: 13.382

4.  Effect of neuroleptic drugs on central catecholamine turnover assessed using tyrosine- and dopamine- -hydroxylase inhibitors.

Authors:  N E Andén; H Corrodi; K Fuxe
Journal:  J Pharm Pharmacol       Date:  1972-03       Impact factor: 3.765

5.  Dopamine, noradrenaline and 5-hydroxy-tryptamine in relation to motor activity, fighting and mounting behavior. I. L-dopa and DL-threo-dihydroxyphenylserine in combination with Ro 4-4602, pargyline and reserpine.

Authors:  O Benkert; H Gluba; N Matussek
Journal:  Neuropharmacology       Date:  1973-03       Impact factor: 5.250

6.  Receptor activity and turnover of dopamine and noradrenaline after neuroleptics.

Authors:  N E Andén; S G Butcher; H Corrodi; K Fuxe; U Ungerstedt
Journal:  Eur J Pharmacol       Date:  1970       Impact factor: 4.432

7.  Sleep: effects of d- and l-amphetamine in man and in rat.

Authors:  E Hartmann; J Cravens
Journal:  Psychopharmacology (Berl)       Date:  1976-11-10       Impact factor: 4.530

8.  The effect of lesions of ascending noradrenaline pathways on sleep and waking in the rat.

Authors:  P Lidbrink
Journal:  Brain Res       Date:  1974-07-05       Impact factor: 3.252

Review 9.  The actions of amphetamine on neurotransmitters: a brief review.

Authors:  K E Moore
Journal:  Biol Psychiatry       Date:  1977-06       Impact factor: 13.382

10.  Regional effects of L-dihydroxyphenylalanine (L-dopa) on norepinephrine metabolism in rat brain.

Authors:  J A Romero; J P Chalmers; K Cottman; L D Lytle; R J Wurtman
Journal:  J Pharmacol Exp Ther       Date:  1972-02       Impact factor: 4.030

  10 in total
  5 in total

1.  Haloperidol and insulin release.

Authors:  F Lechin; B van der Dijs
Journal:  Diabetologia       Date:  1981       Impact factor: 10.122

2.  Daytime alertness in Parkinson's disease: potentially dose-dependent, divergent effects by drug class.

Authors:  Donald L Bliwise; Lynn Marie Trotti; Anthony G Wilson; Sophia A Greer; Cathy Wood-Siverio; Jorge J Juncos; Stewart A Factor; Alan Freeman; David B Rye
Journal:  Mov Disord       Date:  2012-07-02       Impact factor: 10.338

3.  Effects of remoxipride, a dopamine D-2 antagonist antipsychotic, on sleep-waking patterns and EEG activity in rats and rabbits.

Authors:  E Ongini; P Bo; S Dionisotti; M Trampus; F Savoldi
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

4.  Biphasic effects of dopamine D-2 receptor agonists on sleep and wakefulness in the rat.

Authors:  J M Monti; M Hawkins; H Jantos; L D'Angelo; M Fernández
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

5.  Methysergide blocks the sleep suppressant action of quipazine in rats.

Authors:  C Fornal; M Radulovacki
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.